Qureator is proud to announce its participation at ARVO 2025, unveiling its pioneering iPSC-derived 3D outer Blood-Retinal Barrier (oBRB) model. Using Curiochips™ technology, the model faithfully replicates key features of both…
Qureator invites you to unlock your drug’s potential at AACR 2025, booth #5016! Explore how our cutting-edge vascularized 3D tumor models enable advanced evaluation of immuno-oncology drug efficacy and mechanism of action (MOA).
The FDA’s recent decision to phase out mandatory animal testing marks a historic shift in drug development — and Qureator is ready. From the start, Qureator has championed human-relevant, next-generation platforms that better bridge lab models to patient outcomes.
Qureator fills this critical need. By combining physiologically relevant 3D disease models with scalable data generation, the platform bridges the divide between computational discovery and translational impact.
Qureator’s pioneering work in advanced 3D disease modeling was recently spotlighted by the Korean Economic Daily in coverage of our collaboration with SillaJen Inc.
Qureator is excited to announce its upcoming presentation at the WuXi AppTec Japan webinar on March 12, 2025.
Qureator is thrilled to announce the appointment of Dr. Branka Mitrovic, a distinguished leader in translational research and therapeutic innovation.
Qureator proudly announces the promotion of Dr. Tsung-li Liu to Chief Technology Officer (CTO).
Qureator extends a heartfelt thank you to CSEM for hosting an outstanding event at the Next-Generation Organ-on-Chips & Organoids Workshop held on February 13th in Basel.